Generics

[anonymous]

Which company is buying us?

 

[anonymous]

Noooooobodddy baby - keith sweat

 

[anonymous]

Exactly. Let me break it down for you. Our card program was designed for off label prescribing, not to drive demand until coverage comes on board. If the latter was the case, it would have been cut off already with our ‘amazing’ coverage. When you add this program to the dog whistle press releases that we will be having the exact same formulation for AD- - >you get the vast majority of rxs being written off label. This means we have bought our volume, and biz development officers realize the launch of the century is all a sham. Our numbers are already indicative of our AD trajectory and it is time to look elsewhere. None of us will be rich with our worthless shares. Look and dig deeper. Future is bleak. Best thing going for us is our non competes are gone!

 

[anonymous]

Albeit I agree with some of your sentiments, your claim about off label use is categorically incorrect. >90% is written for PsO.

 

[anonymous]

We need to go all in on combination therapy with a systemic therapy, regardless of which one it is. Come on Darden, find a way.